Wells Fargo’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-20,000
Closed -$1.56M 7176
2025
Q2
$1.56M Buy
+20,000
New +$1.49M ﹤0.01% 3400
2021
Q3
Sell
-1,200
Closed -$124K 7094
2021
Q2
$124K Hold
1,200
﹤0.01% 5217
2021
Q1
$100K Buy
+1,200
New +$101K ﹤0.01% 5484
2018
Q3
Sell
-1,200
Closed -$2K 6443
2018
Q2
$2K Buy
+1,200
New +$56K ﹤0.01% 6182
2017
Q1
Sell
-177,300
Closed -$18K 6355
2016
Q4
$18K Buy
+177,300
New +$5.74M ﹤0.01% 5655
2015
Q1
Sell
-52,800
Closed -$38K 6221
2014
Q4
$38K Buy
+52,800
New +$1.06M ﹤0.01% 5121
2013
Q4
Sell
-6,000
Closed -$5K 5782
2013
Q3
$5K Buy
+6,000
New +$70.2K ﹤0.01% 5275

Other funds holding EW

Wells Fargo's EW Position: Q2 2026 in Review

Wells Fargo reduced its Edwards Lifesciences (EW) stake by 3.7% in Q2 2026, selling an estimated $3.32M and leaving 1,041,675 shares worth $94.2M. The position accounts for 0.02% of the portfolio, ranked #707.

Wells Fargo first reported a position in EW in Q2 2013 and has held it in 53 quarters since. The position peaked at $483M in Q2 2021. 1,333 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Wells Fargo held 1,041,675 shares of Edwards Lifesciences worth $94.2M as of Q2 2026.
  • Wells Fargo sold 39,596 Edwards Lifesciences shares in Q2 2026, an estimated $3.32M.
  • Edwards Lifesciences made up 0.02% of Wells Fargo's portfolio in Q2 2026, its #707 holding.
  • Wells Fargo first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 53 quarters since.
  • Wells Fargo's Edwards Lifesciences position peaked at $483M in Q2 2021.
  • 1,333 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.